Scilex Holding (SCLX) Other Working Capital Changes (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Other Working Capital Changes of $1.6 million for Q1 2026, up 1351.16% year-over-year from $111221.2 in Q1 2025, and down 76.3% on a QoQ basis from $6.8 million in Q4 2025.
Scilex Holding (SCLX) Other Working Capital Changes (2021 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Other Working Capital Changes for 6 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 1351.16% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.7 million (up 241.9% YoY), while the FY2025 annual figure was -$13000.0, down 101.97% from the prior year.
- Other Working Capital Changes came in at $1.6 million for Q1 2026 at Scilex Holding, down from $6.8 million in the prior quarter.
- The five-year high for Other Working Capital Changes was $6.8 million in Q4 2025, with the low at -$6.9 million in Q3 2025.
- Average Other Working Capital Changes over 5 years is $309250.0, with a median of $116500.0 recorded in 2024.
- The largest YoY upside for Other Working Capital Changes was 2431.6% in 2025 against a maximum downside of 2135.4% in 2025.
- Year by year, Other Working Capital Changes stood at -$849000.0 in 2022, then rose by 20.61% to -$674000.0 in 2023, then surged by 139.91% to $269000.0 in 2024, then soared by 2431.6% to $6.8 million in 2025, then tumbled by 76.3% to $1.6 million in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered $1.6 million, $6.8 million, and -$6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 6.81 Mn |
| Dec 31, 2025 | 6.81 Mn |
| Dec 31, 2025 | 6.81 Mn |
| Sep 30, 2025 | -6.90 Mn |
| Sep 30, 2025 | -6.90 Mn |
| Sep 30, 2025 | -6.90 Mn |
| Jun 30, 2025 | 206,000.00 |
| Jun 30, 2025 | 206,000.00 |
| Jun 30, 2025 | 206,000.00 |
| Mar 31, 2025 | -129,000.00 |
| Mar 31, 2025 | -129,000.00 |
| Mar 31, 2025 | -129,000.00 |
| Dec 31, 2024 | 269,000.00 |
| Dec 31, 2024 | 269,000.00 |
| Dec 31, 2024 | 269,000.00 |
| Sep 30, 2024 | 339,000.00 |
| Sep 30, 2024 | 339,000.00 |